Thursday, September 14, 2017

4:00 - 6:00 pm  Registration

6:00 - 6:10 pm  Opening Ceremony and Welcome  
F.R. Hirsch, E. Vokes, J. Patel

6:10 - 7:30 pm  Keynote Addresses
6:10 - 6:30 pm  Beyond Approved PD-1/PD-L1 Strategies: Biomarkers Besides PD-L1 and IO Combinations Likely to Change Practice in the Near Term  
Hossein Borghaei

6:30 - 6:50 pm  On the Edge: IO Toxicity Management and Use in Patients with Underlying Autoimmunity  
Matthew Hellmann

6:50 - 7:10 pm  The Interplay of IO and Radiation Therapy  
Roy Decker

7:10 - 7:30 pm  Patient Perspective on ASCO Value Framework in Cancer Care  
Janet Freeman-Daily

7:30 - 9:00 pm  Dinner/Symposium sponsored by AstraZeneca
Friday, September 15, 2017

7:00 am - 5:00 pm  Registration

7:00 - 8:00 am  Breakfast Symposium sponsored by AstraZeneca

7:00 - 8:00 am  Breakfast in the registration area

8:00 - 8:05 am  Welcome  F.R. Hirsch, E. Vokes, J. Patel, H. Wakelee

8:05 - 8:20 am  Research and Policy Priorities in Tobacco Control  Stephanie Land

8:20 - 8:35 am  Barriers to Widespread Lung Cancer Screening  James Mulshine

8:35 - 8:50 am  Pulmonologists in the Era of Precision Oncology  Colin Gillespie

8:50 - 9:05 am  Optimal Tissue Utilization in the Molecular and IO Era  Jeremy Segal

9:05 - 9:20 am  Blood-based Biomarkers in Thoracic Oncology  Max Diehn

9:20 - 9:35 am  Access to Care, Cost and Health Disparities—Shifting Sands  Robert Winn

9:35 - 10:05 am  Oligometastatic Disease and Synchronous Primaries—Optimal Approaches  Puneeth Iyengar  Bulent Arslan  Jessica Donington

10:05 - 10:30 am  Break

10:30 am - Noon  Highlighted Oral Abstract Session 1

Noon - 1:30 pm  Lunch Symposium sponsored by Takeda

Noon - 1:30 pm  Lunch in the registration area

1:30 - 3:00 pm  Education Session 1A/1B 1:30 - 2:15 pm; Session 2A/2B 2:15 - 3:00 pm

1:30 - 2:15 pm  Breakout Session 1A: Thoracic Surgery at the “Cutting Edge”  
  Multiple Lung Nodules and GGOs—When to Cut?  Malcolm DeCamp  
  Staging Updates—Invasive vs. Radiographic  Linda Martin  
  Complex Resection in Pleural Diseases (mesothelioma/thymic)  Reza Mehran

1:30 - 2:15 pm  Breakout Session 1B: Collateral Damage in a New Era of Lung Cancer Treatment  
  Cardio-oncology Issues  Cliff Robinson  
  Toxicity Concerns with Targeted and Novel Therapies  Ken Rosenzweig
Protons for Thoracic Indications to Reduce Toxicity  
Jim Urbanic

2:15 - 3:00 pm  
Breakout Session 2A: Team Based Care in Oncology  
Challenges and Opportunities of Team-Based Care  
David Gerber

Symptom Management Partnerships  
Kavitha Ramchandran & Alison Tisch

Shared Goal Setting for Elderly Patients with Lung Cancer  
Monica Malec

2:15 - 3:00 pm  
Breakout Session 2B: In the Perioperative Setting  
Neoadjuvant/Adjuvant Updates  
Jamie Chaft

Importance of Lymph Node Sampling  
Ray Osarogiagbon

Surveillance Imaging  
Leah Backhus

3:00 - 3:30 pm  
Break

3:30 - 4:25 pm  
Breakout Sessions Highlighting Work by Junior Investigators

3:30 - 4:10 pm  
Session 3A/3B

4:15 - 5:00 pm  
Session 4A/4B

Proposed sessions could include:  
- translational science (including novel model systems)  
- TKI and other therapeutic resistance  
- surgical outcomes, patient selection  
- quality/palliative care/patient education

(Note: topics may change based on abstracts submitted by junior faculty)

4:30 - 5:10 pm  
Highlighted Oral Abstract Session 2 – Immunotherapy-focused

5:10 - 5:30 pm  
Poster Discussion  
Local Therapy and Translational Science  
Metastatic Disease

5:30 - 6:30 pm  
Poster Viewing and Reception

6:30 - 8:30 pm  
Dinner Symposium sponsored by BMS

Saturday, September 16, 2017

7:00 am – Noon  
Registration
7:00 - 8:00 am
Breakfast Symposium sponsored by AstraZeneca

8:00 - 8:45 am
Tumor Board – Moderated by Tim Murgu
Faculty: Aliya N. Husain, Jessica Donington, Doug Arenberg, Tim Kruser, Tom Hensing, Heather Wakelee

8:45 - 10:15 am
Highlighted Oral Session 3

10:15 - 10:30 am
Break

10:30 - 11:55 am
Year in Review
Beyond EGFR and ALK
Staging Updates – AJCC
Debate: Should Patients with EGFR Mutation NSCLC Postpone Brain Radiation for Brain Metastasis?
Pro: Lecia Sequist
Con: Laurie Gaspar
Debate: Should All Patients with NSCLC Receive First-Line Immunotherapy?
Pro: Jyoti Patel
Con: John Heymach
Stage III NSCLC: Current Status, Next Steps
Everett Vokes

11:55 am - Noon
Closing Remarks